Innoviva, Inc. (INVA) - NASDAQ
  • Oct. 2, 2015, 5:37 PM
    • Top gainers, as of 5.25 p.m.: RGS +7.3%. OFG +5.7%. EZPW +4.3%. IBKR +4.2%.
    • Top losers, as of 5.25p.m.: XNPT -19.0%. THRX -11.5%. HLX -11.8%. CDE -11.5%.
    | Oct. 2, 2015, 5:37 PM
  • Oct. 1, 2015, 5:35 PM
    | Oct. 1, 2015, 5:35 PM
  • Sep. 9, 2015, 12:44 PM
    | Sep. 9, 2015, 12:44 PM
  • Mar. 20, 2015, 9:23 AM
    | Mar. 20, 2015, 9:23 AM | 2 Comments
  • Mar. 19, 2015, 7:24 PM
    • Theravance (NASDAQ:THRX) has fallen to $16.11 in AH trading after the FDA advisory committee backed the use of GlaxoSmithKline's Breo Ellipta inhaler for treating asthma in adults, but not in adolescents.
    • Theravance, which co-developed Breo Ellipta with Glaxo and receives royalties on its sale, was halted today in advance of the decision. CEO Michael Aguiar, discussing the decisions in a PR: "We remain committed to the ongoing review process and will be fully cooperating with the FDA to ensure it has all it needs to consider the sNDA for Breo Ellipta in asthma. We look forward to the final outcome expected in April."
    | Mar. 19, 2015, 7:24 PM
  • Feb. 13, 2015, 5:36 PM
    • Top gainers, as of 5:15 p.m.: IRWD +5.9%. HK +5.0%. EGY +4.8%. CAG +4.3%. TTS +3.5%.
    • Top losers, as of 5:15 p.m.: PES -9.7%. LOGM -7.7%. HOS -7.2%. THRX -6.4%. BTU -6.3%.
    | Feb. 13, 2015, 5:36 PM | 3 Comments
  • Jun. 3, 2014, 12:46 PM
    | Jun. 3, 2014, 12:46 PM | 2 Comments
  • May 6, 2014, 4:55 PM
    • Theravance (THRX): Q1 EPS of -$0.62 misses by $0.11.
    • Revenue of $0.17M (-87.3% Y/Y) misses by $4.35M.
    • Shares +1.18%.
    | May 6, 2014, 4:55 PM
  • Nov. 13, 2013, 4:42 PM
    • Theravance (THRX) discloses its TD-9855 drug did not meet the primary efficacy endpoint in Phase 2 study in adult patients with ADHD/hyperactivity disorder and will scrap the program.
    • TD-9855 is still being evaluated in an ongoing Phase 2 study in patients with fibromyalgia; results are anticipated during H1 2014.
    • Shares -3.4% AH.
    | Nov. 13, 2013, 4:42 PM
  • Sep. 10, 2013, 4:12 PM
    • The FDA'a Pulmonary-Allergy Drugs Advisory Committee votes 11 yes to 2 no that the efficacy and safety data provides substantial evidence to support approval of GlaxoSmithKline's (GSK) and Theravance's (THRX) Ellipta for the maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
    • THRX to resume trading shortly
    | Sep. 10, 2013, 4:12 PM | 1 Comment
  • Aug. 1, 2013, 5:20 PM
    • Theravance (THRX) says the FDA's Pulmonary-Allergy Drugs Advisory Committee will discuss the company's NDA for the COPD treatment Anoro Ellipta on September 10. (PR)
    • Shares +1.5% AH.
    | Aug. 1, 2013, 5:20 PM
  • Jun. 21, 2013, 9:10 AM
    Premarket gainers: SPRD +22%. NVGN +12%. KMX +8%. THRX +7%. MTL +7%.
    Losers: IDIX -35%. ORCL -8%. AHT -5%.
    | Jun. 21, 2013, 9:10 AM
  • Jun. 17, 2013, 7:17 AM

    Elan (ELN) flies 8.3% premarket after investors approve a $200M share repurchase plan, meaning Royalty Pharma's bid for the company has now lapsed, freeing Elan to seek other buyers. Also rejected is a deal with Theravance (THRX) and the acquisition of AOP Orphan Pharmaceuticals.

    | Jun. 17, 2013, 7:17 AM
  • Jun. 4, 2013, 2:05 PM

    Institutional Shareholder Services is recommending Elan (ELN +0.6%) shareholders vote against several company proposals - including a $1B royalty-sharing agreement with Theravance (THRX -1.5%) and a $200M stock buyback program at ELN's June 17 special meeting. It withholds recommendation on the Royalty all-cash offer however, although it said voting against ELN's proposals "leaves the door open for shareholders to tender their shares if they so wish."

    | Jun. 4, 2013, 2:05 PM
  • May 13, 2013, 9:10 AM
    Premarket gainers: UNIS +25%. SUTR +20%. THRX +13%. PERI +13%. NBG +11%. IGLD +10%. TSLA +6%. CSIQ +5%. SPWR +5%.
    Losers: AFFY -8%. UNXL -5%.
    | May 13, 2013, 9:10 AM
  • May 10, 2013, 12:09 PM

    GlaxoSmithKline (GSK +1.5%) and Theravance (THRX +11%) both move higher today after the FDA approves Breo Ellipta for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema. The approval was widely expected after a federal advisory panel endorsed the product last month.

    | May 10, 2013, 12:09 PM
Company Description
Theravance, Inc. is a biopharmaceutical company, with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. It engages in the discovery, development and commercialization of small molecule medicines across a number of therapeutic... More
Sector: Healthcare
Industry: Biotechnology
Country: United States